CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 11 January 2001 (11.01.2001)

PCT

(10) International Publication Number WO 01/02557 A1

- (51) International Patent Classification⁷: C12N 15/11, 15/12, C07K 14/71, C12Q 1/68, A61K 38/17, 48/00, G01N 33/50
- (21) International Application Number: PCT/EP00/04918
- (22) International Filing Date: 26 May 200

26 May 2000 (26.05.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 9915200.1

29 June 1999 (29.06.1999) GB

- (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MASURE, Stefan, Leo, Jozef [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). CIK, Miroslav [HR/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). HOEFNAGEL, Evert, Wilhelmus [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).
- (74) Agent: BALDOCK, Sharon, Claire; Boult Wade Tennant, Verulam Gardens, 70 Grays Inn Road, London WC1X 8BT (GB).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- (48) Date of publication of this corrected version: 29 March 2001
- (15) Information about Correction: see PCT Gazette No. 13/2001 of 29 March 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

0 9 APR 2001

(54) Title: NEUROTROPHIC FACTOR RECEPTOR

(57) Abstract: There is disclosed a mammalian receptor protein designated GFRα-4 and the nucleic acid sequence encoding therefor. Also provided is an expression vector comprising the nucleic acid sequence and host cells transformed or transfected with the vector. Host cells expressing the receptor may be used to identify agonists or antagonists in relation to the receptor.

1/02557 A





From the INTERNATIONAL BUREAU

PCT

COMMUNICATION IN CASES FOR WHICH NO OTHER FORM IS APPLICABLE

To:

BALDOCK, Sharon, Claire Boult Wade Tennant Verulam Gardens 70 GrayÚs Inn Road London WC1X 8BT ROYAUME-UNI

Miss Baldock Con H3/01 NATS 29/12/05

	NATS 29	112/01
Date of mailing (day/month/year) 27 February 2001 (27.02.01)	LB 7	
Applicant's or agent's file reference SCB/53202001	REPLY DUE see paragraph 1 below	
International application No.	International filing date (day/month/year)	
PCT/EP00/04918	26 May 2000 (26.05.00)	
Applicant JANSSEN PHARMACEUTICA N.V.		
REPLY DUE within months/days from the NO REPLY DUE, however, see below	e above date of mailing	
IMPORTANT COMMUNICATION		
INFORMATION ONLY	·	
2. COMMUNICATION:		
The International Bureau acknowledges receipt of your letter dated 30 January 2001 (30.01.01) concerning an error in the publication of above-mentioned international application (the published drawing had nothing to do with the international application).		
	error and the inconvenience it may have	caused and on
29 March 2001 (29.03.01).		
RECEIVED		
0 5 MAR 2001		
ECHIAMASE AEMINA		
20000	Authorized officer	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

N. Wagner

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 338.83.38